Slingshot members are tracking this event:

Phase 3 Studies of Tanezumab for Chronic Pain Resume After Partial Clinical Hold

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details Pfizer Inc.  and Eli Lilly and Company announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. A partial clinical hold has been in place for tanezumab and all other anti-nerve growth factor antibodies since December 2012 due to adverse changes in the sympathetic nervous system of mature animals. Studies in terminal cancer pain were allowed to proceed.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 23, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Chronic Pain, Tanezumab, Phase 3 Study, Partial Clinical Hold